Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Over the last 20 years, we’ve seen major strides in the treatment options for major depressive disorder. We now understand that depression isn’t the same for everyone. The idea is to identify ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Cite this: Duloxetine in the Treatment of Major Depressive Disorder: An Open-Label Study - Medscape - Aug 28, 2007.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

When you have major depressive disorder (MDD), understanding what ... to see a trend toward improved symptoms over time. If your treatment stalls or stops working, talk to your therapist.

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

TMS services are available at the Hays Main Office of High Plains Mental Health Center, 208 E. Seventh St. For more ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder. The San Diego ...

Researchers develop machine learning tools that screen for co-morbid anxiety disorders and major depressive disorder using acoustic voice signals. The team spoke to participants with and without ...